Praxis Receives FDA Priority Review for Relutrigine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 14 hours ago
0mins
Should l Buy PRAX?
Source: Newsfilter
- FDA Review Progress: Praxis Precision Medicines announced that its New Drug Application (NDA) has been accepted for priority review by the FDA, with a target action date of September 27, 2026, marking a significant milestone in the company's evolution towards commercialization, as approval would make it the first disease-modifying therapy for SCN2A and SCN8A developmental epileptic encephalopathies.
- Clinical Trial Results: The NDA is supported by positive results from the EMBOLD study, which was stopped early for efficacy, demonstrating significant therapeutic effects of relutrigine in patients with severe epilepsy, potentially improving their quality of life.
- Drug Designations: Relutrigine has received Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations from the FDA, and if approved, it will be eligible for a Pediatric Review Voucher, enhancing its competitive position in the market.
- Future Research Plans: The drug is also being investigated in the EMERALD trial for broader DEEs, expected to be completed by the end of 2026, showcasing Praxis's ongoing innovation and commitment in the epilepsy treatment space.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRAX
Wall Street analysts forecast PRAX stock price to rise
15 Analyst Rating
14 Buy
0 Hold
1 Sell
Strong Buy
Current: 290.100
Low
95.00
Averages
456.71
High
843.00
Current: 290.100
Low
95.00
Averages
456.71
High
843.00
About PRAX
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Praxis Receives FDA Priority Review for Relutrigine
- FDA Review Progress: Praxis Precision Medicines announced that its New Drug Application (NDA) has been accepted for priority review by the FDA, with a target action date of September 27, 2026, marking a significant milestone in the company's evolution towards commercialization, as approval would make it the first disease-modifying therapy for SCN2A and SCN8A developmental epileptic encephalopathies.
- Clinical Trial Results: The NDA is supported by positive results from the EMBOLD study, which was stopped early for efficacy, demonstrating significant therapeutic effects of relutrigine in patients with severe epilepsy, potentially improving their quality of life.
- Drug Designations: Relutrigine has received Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations from the FDA, and if approved, it will be eligible for a Pediatric Review Voucher, enhancing its competitive position in the market.
- Future Research Plans: The drug is also being investigated in the EMERALD trial for broader DEEs, expected to be completed by the end of 2026, showcasing Praxis's ongoing innovation and commitment in the epilepsy treatment space.
See More
5AM Venture Management Sells Entire Stake in Praxis Precision Medicines
- Stake Sale: On February 17, 2026, 5AM Venture Management disclosed via an SEC filing the sale of its entire 170,000 shares in Praxis Precision Medicines, resulting in an estimated $9.01 million reduction in the fund's quarter-end valuation, indicating a cautious outlook on the company's future performance.
- Market Performance: As of Wednesday, shares of Praxis were priced at $291.70, reflecting a nearly 700% increase over the past year, significantly outperforming the S&P 500's approximately 19% gain; however, the market has begun to price in execution risks, with shares down about 30% since the quarter ended.
- Financial Condition: Praxis reported no meaningful revenue and a net loss of approximately $303 million over the past year, yet raised $621 million in early 2026, ending the year with roughly $926 million in cash, providing a runway into 2028 and highlighting its high-risk, high-reward investment profile in the biotech sector.
- R&D Progress: Praxis focuses on clinical-stage therapies for central nervous system disorders, having filed two New Drug Applications and with multiple late-stage programs approaching key readouts; despite high spending and execution risks, the depth of its pipeline continues to attract investor interest.
See More
Cormorant Asset Management Sells Shares of Praxis Precision Medicines
- Share Reduction Details: Cormorant Asset Management disclosed a sale of 50,000 shares of Praxis Precision Medicines in a February 17, 2026 SEC filing, with an estimated transaction value of $9.31 million, indicating a strategic risk management approach amidst significant stock appreciation.
- Holding Value Increase: By the end of Q4 2025, the total value of Praxis shares held increased by $227 million, reflecting positive impacts from trading and price movements, suggesting strong market confidence in the company.
- Company Overview: Praxis Precision Medicines focuses on developing clinical-stage therapies for central nervous system disorders, with lead candidates targeting major depressive disorder and severe epilepsy, showcasing its innovative potential in the biopharmaceutical sector.
- Strong Financial Position: Praxis ended 2025 with approximately $926 million in cash and investments, and a $621 million public offering in January further bolstered its financial strength, providing ample runway for a potential transition to commercial drug development.
See More
Cormorant Asset Management Reduces PRAX Holdings
- Share Reduction Details: Cormorant Asset Management sold 50,000 shares of PRAX in Q4 2025, with an estimated transaction value of $9.31 million, reflecting the firm's risk management strategy amid market fluctuations.
- Increase in Holdings Value: At quarter-end, Cormorant held 950,000 shares of PRAX valued at $280 million, representing a $227 million increase from the previous quarter, indicating the firm's confidence in the biotech company.
- Strong Financial Position: Praxis Precision Medicines ended 2025 with approximately $926 million in cash and investments, further bolstered by a $621 million public offering, providing ample runway for future operations.
- Outstanding Market Performance: Praxis has emerged as a standout in the neuroscience biotech sector, advancing multiple late-stage therapies for neurological disorders, showcasing its potential to meet significant unmet medical needs.
See More
Deerfield Management Increases Stake in Praxis Precision Medicines
- Increased Stake: On February 17, 2026, Deerfield Management Company purchased an additional 62,500 shares of Praxis Precision Medicines, valued at approximately $11.64 million, indicating strong confidence in the company's future prospects.
- Value Growth: Deerfield's PRAX position saw an increase of $221.69 million in value during Q4 2025, reflecting the positive impact of both trading activity and stock price movements, thereby solidifying its position in the investment portfolio.
- Outstanding Market Performance: As of last Friday, PRAX shares were priced at $303.37, soaring 685% over the past year, significantly outperforming the S&P 500's 19% gain, showcasing the market's high expectations for its future potential.
- Strong Financial Position: Praxis ended 2025 with approximately $926 million in cash and investments, and a follow-on offering in early 2026 added another $621 million, extending its operational runway into 2028, which enhances its competitive edge in the neuroscience sector.
See More
Deerfield Management Increases PRAX Stake by 62,500 Shares
- Stake Increase: Deerfield Management Company increased its stake in PRAX by 62,500 shares in Q4 2025, with an estimated transaction value of $11.64 million, indicating continued confidence in the company.
- Value Growth: As of December 31, 2025, Deerfield held 903,351 shares of PRAX valued at $266.25 million, reflecting a $221.69 million increase over the quarter due to both share additions and price appreciation.
- Strong Financial Position: Praxis Precision Medicines ended 2025 with approximately $926 million in cash and investments, and a follow-on offering in early 2026 added another $621 million, extending its operational runway into 2028.
- Optimistic Market Outlook: If successfully commercialized, Praxis's four leading development programs could represent over $20 billion in potential revenue, highlighting its strategic significance in the neuroscience sector.
See More
Praxis Receives FDA Priority Review for Relutrigine
- FDA Review Progress: Praxis Precision Medicines announced that its New Drug Application (NDA) has been accepted for priority review by the FDA, with a target action date of September 27, 2026, marking a significant milestone in the company's evolution towards commercialization, as approval would make it the first disease-modifying therapy for SCN2A and SCN8A developmental epileptic encephalopathies.
- Clinical Trial Results: The NDA is supported by positive results from the EMBOLD study, which was stopped early for efficacy, demonstrating significant therapeutic effects of relutrigine in patients with severe epilepsy, potentially improving their quality of life.
- Drug Designations: Relutrigine has received Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations from the FDA, and if approved, it will be eligible for a Pediatric Review Voucher, enhancing its competitive position in the market.
- Future Research Plans: The drug is also being investigated in the EMERALD trial for broader DEEs, expected to be completed by the end of 2026, showcasing Praxis's ongoing innovation and commitment in the epilepsy treatment space.
See More
5AM Venture Management Sells Entire Stake in Praxis Precision Medicines
- Stake Sale: On February 17, 2026, 5AM Venture Management disclosed via an SEC filing the sale of its entire 170,000 shares in Praxis Precision Medicines, resulting in an estimated $9.01 million reduction in the fund's quarter-end valuation, indicating a cautious outlook on the company's future performance.
- Market Performance: As of Wednesday, shares of Praxis were priced at $291.70, reflecting a nearly 700% increase over the past year, significantly outperforming the S&P 500's approximately 19% gain; however, the market has begun to price in execution risks, with shares down about 30% since the quarter ended.
- Financial Condition: Praxis reported no meaningful revenue and a net loss of approximately $303 million over the past year, yet raised $621 million in early 2026, ending the year with roughly $926 million in cash, providing a runway into 2028 and highlighting its high-risk, high-reward investment profile in the biotech sector.
- R&D Progress: Praxis focuses on clinical-stage therapies for central nervous system disorders, having filed two New Drug Applications and with multiple late-stage programs approaching key readouts; despite high spending and execution risks, the depth of its pipeline continues to attract investor interest.
See More
Cormorant Asset Management Sells Shares of Praxis Precision Medicines
- Share Reduction Details: Cormorant Asset Management disclosed a sale of 50,000 shares of Praxis Precision Medicines in a February 17, 2026 SEC filing, with an estimated transaction value of $9.31 million, indicating a strategic risk management approach amidst significant stock appreciation.
- Holding Value Increase: By the end of Q4 2025, the total value of Praxis shares held increased by $227 million, reflecting positive impacts from trading and price movements, suggesting strong market confidence in the company.
- Company Overview: Praxis Precision Medicines focuses on developing clinical-stage therapies for central nervous system disorders, with lead candidates targeting major depressive disorder and severe epilepsy, showcasing its innovative potential in the biopharmaceutical sector.
- Strong Financial Position: Praxis ended 2025 with approximately $926 million in cash and investments, and a $621 million public offering in January further bolstered its financial strength, providing ample runway for a potential transition to commercial drug development.
See More
Cormorant Asset Management Reduces PRAX Holdings
- Share Reduction Details: Cormorant Asset Management sold 50,000 shares of PRAX in Q4 2025, with an estimated transaction value of $9.31 million, reflecting the firm's risk management strategy amid market fluctuations.
- Increase in Holdings Value: At quarter-end, Cormorant held 950,000 shares of PRAX valued at $280 million, representing a $227 million increase from the previous quarter, indicating the firm's confidence in the biotech company.
- Strong Financial Position: Praxis Precision Medicines ended 2025 with approximately $926 million in cash and investments, further bolstered by a $621 million public offering, providing ample runway for future operations.
- Outstanding Market Performance: Praxis has emerged as a standout in the neuroscience biotech sector, advancing multiple late-stage therapies for neurological disorders, showcasing its potential to meet significant unmet medical needs.
See More
Deerfield Management Increases Stake in Praxis Precision Medicines
- Increased Stake: On February 17, 2026, Deerfield Management Company purchased an additional 62,500 shares of Praxis Precision Medicines, valued at approximately $11.64 million, indicating strong confidence in the company's future prospects.
- Value Growth: Deerfield's PRAX position saw an increase of $221.69 million in value during Q4 2025, reflecting the positive impact of both trading activity and stock price movements, thereby solidifying its position in the investment portfolio.
- Outstanding Market Performance: As of last Friday, PRAX shares were priced at $303.37, soaring 685% over the past year, significantly outperforming the S&P 500's 19% gain, showcasing the market's high expectations for its future potential.
- Strong Financial Position: Praxis ended 2025 with approximately $926 million in cash and investments, and a follow-on offering in early 2026 added another $621 million, extending its operational runway into 2028, which enhances its competitive edge in the neuroscience sector.
See More
Deerfield Management Increases PRAX Stake by 62,500 Shares
- Stake Increase: Deerfield Management Company increased its stake in PRAX by 62,500 shares in Q4 2025, with an estimated transaction value of $11.64 million, indicating continued confidence in the company.
- Value Growth: As of December 31, 2025, Deerfield held 903,351 shares of PRAX valued at $266.25 million, reflecting a $221.69 million increase over the quarter due to both share additions and price appreciation.
- Strong Financial Position: Praxis Precision Medicines ended 2025 with approximately $926 million in cash and investments, and a follow-on offering in early 2026 added another $621 million, extending its operational runway into 2028.
- Optimistic Market Outlook: If successfully commercialized, Praxis's four leading development programs could represent over $20 billion in potential revenue, highlighting its strategic significance in the neuroscience sector.
See More
